Key Points
- Elanco CEO Jeffrey Simmons bought 4,971 shares on May 15 at an average price of $20.09 each, spending about $99,867. The purchase increased his ownership by 2.98% to 171,971 shares.
- Elanco recently beat quarterly expectations, reporting EPS of $0.40 versus $0.34 expected and revenue of $1.37 billion versus $1.28 billion expected. Revenue rose 14.9% year over year, and the company guided for full-year 2026 EPS of $1.03 to $1.09.
- Wall Street remains cautiously optimistic on ELAN, with a consensus rating of “Moderate Buy” and an average price target of $28.20. Several analysts recently raised targets, though one rating was downgraded by Weiss Ratings.
Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) CEO Jeffrey Simmons purchased 4,971 shares of the stock in a transaction that occurred on Friday, May 15th. The shares were bought at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the acquisition, the chief executive officer owned 171,971 shares of the company's stock, valued at approximately $3,454,897.39. The trade was a 2.98% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Elanco Animal Health Stock Performance
NYSE ELAN opened at $19.78 on Wednesday. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. Elanco Animal Health Incorporated has a 52-week low of $12.40 and a 52-week high of $27.72. The business's 50-day moving average price is $23.16 and its 200 day moving average price is $23.31. The firm has a market cap of $9.88 billion, a P/E ratio of -39.55, a P/E/G ratio of 2.14 and a beta of 1.69.
Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same quarter last year, the company posted $0.37 earnings per share. The business's revenue was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, equities research analysts expect that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current year.
Hedge Funds Weigh In On Elanco Animal Health
Hedge funds have recently bought and sold shares of the company. NewEdge Advisors LLC increased its stake in Elanco Animal Health by 133.7% in the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company's stock valued at $25,000 after purchasing an additional 627 shares in the last quarter. Huntington National Bank increased its stake in Elanco Animal Health by 136.7% in the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company's stock valued at $38,000 after purchasing an additional 1,087 shares in the last quarter. Root Financial Partners LLC increased its stake in Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company's stock valued at $40,000 after purchasing an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. purchased a new position in Elanco Animal Health in the 4th quarter valued at approximately $41,000. Finally, Whittier Trust Co. of Nevada Inc. increased its stake in Elanco Animal Health by 80.3% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company's stock valued at $42,000 after purchasing an additional 900 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
ELAN has been the topic of a number of research reports. Citigroup raised their price target on Elanco Animal Health from $30.00 to $31.00 and gave the stock a "buy" rating in a report on Thursday, May 7th. Leerink Partners raised their price objective on shares of Elanco Animal Health from $26.00 to $30.00 and gave the company an "outperform" rating in a research report on Tuesday, February 24th. JPMorgan Chase & Co. raised their price objective on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an "overweight" rating in a research report on Thursday, May 7th. Morgan Stanley raised their price objective on shares of Elanco Animal Health from $22.00 to $24.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 25th. Finally, Weiss Ratings downgraded shares of Elanco Animal Health from a "sell (d+)" rating to a "sell (d)" rating in a research report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $28.20.
Check Out Our Latest Stock Analysis on Elanco Animal Health
Elanco Animal Health Company Profile
(
Get Free Report)
Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.
Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
